Cardiometabolic outcomes in children and adolescents following discontinuation of long-term risperidone treatment.

@article{Calarge2014CardiometabolicOI,
  title={Cardiometabolic outcomes in children and adolescents following discontinuation of long-term risperidone treatment.},
  author={Chadi A Calarge and Ginger Nicol and Janet A. Schlechte and Trudy L. Burns},
  journal={Journal of child and adolescent psychopharmacology},
  year={2014},
  volume={24 3},
  pages={120-9}
}
OBJECTIVE Second-generation antipsychotics (SGAs) cause weight gain and cardiometabolic abnormalities in children and adolescents. Less well-investigated is the outcome of these adverse events following SGA discontinuation, which we examined. METHODS Medically healthy 7 to 17-year-old patients treated with risperidone for ≥6 months were enrolled and returned for follow-up, 1.5 years later. Treatment history was extracted from the medical and pharmacy records. Anthropometric and laboratory… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 3 times. VIEW TWEETS

Citations

Publications citing this paper.

References

Publications referenced by this paper.
Showing 1-10 of 47 references

CU: National trends in the office-based treatment of children, adolescents, and adults with antipsychotics

M Olfson, C Blanco, SM Liu, S Wang, Correll
Arch Gen Psychiatry • 2012

Similar Papers

Loading similar papers…